PMID- 14535953
OWN - NLM
STAT- MEDLINE
DCOM- 20031124
LR  - 20190630
IS  - 0022-3042 (Print)
IS  - 0022-3042 (Linking)
VI  - 87
IP  - 3
DP  - 2003 Nov
TI  - Expression of BDNF mRNA in substantia nigra is dependent on target integrity and 
      independent of neuronal activation.
PG  - 709-21
AB  - We have analyzed the regulation of brain-derived neurotrophic factor (BDNF) mRNA 
      expression in the nigrostriatal system following neurotoxin ablation of striatal 
      targets by means of kainate (KA) or quinolinic acid (QA) injections. Loss of 
      nigral target cells in the striatum was accompanied by significant induction of 
      BDNF mRNA levels in the ipsilateral substantia nigra (SN) at 12 and 24 h post 
      lesion. Dual tyrosine hydroxylase (TH) and BDNF mRNA in situ hybridization (ISH) 
      confirmed the dopaminergic nature of the BDNF mRNA expressing cells. Analysis of 
      neuronal activity in terms of cFos mRNA expression demonstrated intense induction 
      of this marker in the ipsilateral SN pars reticulata (SNPR), but not in SN pars 
      compacta. Dual glutamic acid decarboxylase (GAD) and cFos mRNA ISH confirmed this 
      view. Colchicine injections into the medial forebrain bundle to specifically 
      disrupt neuronal trafficking between SN and striatum induced BDNF mRNA levels in 
      the ipsilateral SNPC, thus demonstrating that nigral expression of BDNF mRNA is 
      dependent of striatal target tissue. In addition, we found significant elevations 
      of BDNF in the subthalamic nucleus following striatal excitotoxic lesion, which 
      may bring novel roles of BDNF in the basal ganglia complex.
FAU - Rite, Inmaculada
AU  - Rite I
AD  - Departamento de Bioquimica, Bromatologia, Toxicologia y Medicina Legal, Facultad 
      de Farmacia, Universidad de Sevilla, Spain.
FAU - Venero, Jose L
AU  - Venero JL
FAU - Tomas-Camardiel, Mayka
AU  - Tomas-Camardiel M
FAU - Machado, Alberto
AU  - Machado A
FAU - Cano, Josefina
AU  - Cano J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Neurochem
JT  - Journal of neurochemistry
JID - 2985190R
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Neurotoxins)
RN  - 0 (RNA, Messenger)
RN  - EC 2.7.10.1 (Receptor, trkB)
RN  - F6F0HK1URN (Quinolinic Acid)
RN  - SIV03811UC (Kainic Acid)
RN  - SML2Y3J35T (Colchicine)
SB  - IM
MH  - Animals
MH  - Axonal Transport/drug effects
MH  - Brain-Derived Neurotrophic Factor/*genetics
MH  - Cerebral Cortex/metabolism/pathology
MH  - Colchicine/pharmacology
MH  - Female
MH  - Kainic Acid
MH  - Medial Forebrain Bundle/drug effects
MH  - Neurodegenerative Diseases/chemically induced/*metabolism/pathology
MH  - Neurons/drug effects/*metabolism/pathology
MH  - Neurotoxins
MH  - Quinolinic Acid
MH  - RNA, Messenger/*biosynthesis
MH  - Rats
MH  - Rats, Wistar
MH  - Receptor, trkB/genetics
MH  - Substantia Nigra/drug effects/*metabolism/pathology
MH  - Subthalamic Nucleus/metabolism/pathology
MH  - Up-Regulation/drug effects
EDAT- 2003/10/11 05:00
MHDA- 2003/12/03 05:00
CRDT- 2003/10/11 05:00
PHST- 2003/10/11 05:00 [pubmed]
PHST- 2003/12/03 05:00 [medline]
PHST- 2003/10/11 05:00 [entrez]
AID - 2041 [pii]
AID - 10.1046/j.1471-4159.2003.02041.x [doi]
PST - ppublish
SO  - J Neurochem. 2003 Nov;87(3):709-21. doi: 10.1046/j.1471-4159.2003.02041.x.